KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Operating Margin (2017 - 2025)

Sarepta Therapeutics has reported Operating Margin over the past 12 years, most recently at 92.92% for Q4 2025.

  • Quarterly results put Operating Margin at 92.92% for Q4 2025, down 11748.0% from a year ago — trailing twelve months through Dec 2025 was 31.83% (down 4330.0% YoY), and the annual figure for FY2025 was 31.83%, down 4330.0%.
  • Operating Margin for Q4 2025 was 92.92% at Sarepta Therapeutics, down from 25.89% in the prior quarter.
  • Over the last five years, Operating Margin for SRPT hit a ceiling of 24.56% in Q4 2024 and a floor of 948.91% in Q2 2022.
  • Median Operating Margin over the past 5 years was 33.11% (2025), compared with a mean of 159.94%.
  • Biggest five-year swings in Operating Margin: soared 78902bps in 2021 and later plummeted -84678bps in 2022.
  • Sarepta Therapeutics' Operating Margin stood at 52.52% in 2021, then surged by 74bps to 13.75% in 2022, then soared by 117bps to 2.28% in 2023, then skyrocketed by 975bps to 24.56% in 2024, then crashed by -478bps to 92.92% in 2025.
  • The last three reported values for Operating Margin were 92.92% (Q4 2025), 25.89% (Q3 2025), and 18.91% (Q2 2025) per Business Quant data.